An injectable photopolymerizable chitosan hydrogel doped anti-inflammatory peptide for long-lasting periodontal pocket delivery and periodontitis therapy

Int J Biol Macromol. 2023 Dec 1:252:126060. doi: 10.1016/j.ijbiomac.2023.126060. Epub 2023 Jul 29.

Abstract

Periodontitis is a common chronic inflammatory disease caused by plaque that leads to alveolar bone resorption and tooth loss. Inflammation control and achieving better tissue repair are the key to periodontitis treatment. In this study, human β-Defensin 1 short motif Pep-B with inflammation inhibition and differentiation regulation properties, is firstly used in the treatment of periodontitis, and an injectable photopolymerizable Pep-B/chitosan methacryloyl composite hydrogel (CMSA/Pep-B) is constructed. We confirm that Pep-B improves inflammation, and restores osteogenic behavior and function of injured stem cells. CMSA/Pep-B has good injectability, fluidity and photopolymerizability, and can sustainably release Pep-B to maintain drug concentration in periodontal pockets. Furthermore, animal experiments showed that CMSA/Pep-B significantly ameliorated the inflammation of the periodontium and reduced the alveolar bone loss by decreasing inflammatory infiltration, osteoclast formation and collagen destruction. In conclusion, CMSA/Pep-B is envisaged to be a novel bioactive material or therapeutic drug for treating periodontitis.

Keywords: Anti-inflammation; Hydrogel; Injectable; Periodontal preservation; Periodontitis.

MeSH terms

  • Alveolar Bone Loss* / drug therapy
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Chitosan* / therapeutic use
  • Humans
  • Hydrogels / therapeutic use
  • Inflammation / drug therapy
  • Periodontal Pocket / complications
  • Periodontal Pocket / drug therapy
  • Periodontitis* / drug therapy

Substances

  • Chitosan
  • Hydrogels
  • Anti-Inflammatory Agents